anti-GPC3 CAR-T / AstraZeneca - LARVOL DELTA

Anti GPC3 CAR T lymphocytes effectively target NSCLC, including chemoresistant stem like cells (AACR 2026) - "GPC3 emerges as an effective and promising target for cell-based immunotherapy in lung cancer. Although preliminary, our data support the concept that anti-GPC3 CAR-T cells can effectively eliminate the CSC-enriched tumor compartment, which is believed to drive chemoresistance and recurrence, thus providing a rationale for future clinical development of cell-based immunotherapies in advanced or relapsed non-responsive lung cancer."

CAR T-Cell Therapy • IO biomarker • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • POU5F1

Tyrosine kinase inhibitor combination therapies with AZD5851, dominant-negative TGFβRII armored anti-GPC3 CAR-T, for the treatment of hepatocellular carcinoma (AACR 2025) - P1/2 | "The multi-target tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib are licensed for first line treatment of advanced/recurrent HCC. The TKI lenvatinib enhances TGFβRII dominant-negative receptor armored GPC3 CAR-T (AZD5851) anti-tumor efficacy in vivo without affecting acute CAR-T viability, proliferation, activation, effector cytokine production, and cytotoxicity. Therefore, combining AZD5851 with lenvatinib may be a promising combination therapeutic regimen for patients with HCC."

CAR T-Cell Therapy • Combination therapy • Hepatocellular Cancer • Oncology • Solid Tumor • FGFR • TGFB1